Up a level |
Salamat, JM and Abbott, KL and Gill, KS and Flannery, PC and Biancardi, VC and Boothe, DM and Huang, C-CJ and Mani, S and Chandran, A and Vishveshwara, S and Onteru, SK and Dhanasekaran, M and Pondugula, SR (2021) Insights into Mechanisms and Models for Studying Neurological Adverse Events Mediated by Pharmacokinetic Interactions between Clinical Drugs and Illicit Substances of Herbal and Fungal Origin. [Book Chapter]
Abbott, KL and Chaudhury, CS and Chandran, A and Vishveshwara, S and Dvorak, Z and Jiskrova, E and Poulikova, K and Vyhlidalova, B and Mani, S and Pondugula, SR (2019) Belinostat, at its clinically relevant concentrations, inhibits rifampicin-induced CYP3A4 and MDR1 gene expressions. In: Molecular Pharmacology, 95 (3). pp. 324-334.